Skip to content

INNOVATION PHARMACEUTICALS INC.: 10-Q/A filed 2014-05-16

What INNOVATION PHARMACEUTICALS INC. reported in its quarterly report amendment filed 2014-05-16 (fiscal Q3 2014): 21 published measures, 86 facts as tagged in accession 0001477932-14-002681.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-Q/A (quarterly report amendment)
Filed
2014-05-16
Fiscal period
fiscal Q3 2014
Accession
0001477932-14-002681 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All INNOVATION PHARMACEUTICALS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-03-3110,301,955USD
At 2013-06-302,970,513USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-03-31910,938USD
At 2013-06-30-5,170,162USD
At 2012-06-30-7,625,997USD
At 2011-06-30-7,288,078USD
At 2010-06-30-4,797,618USD
At 2009-06-30-1,793,059USD
At 2008-06-30-361,990USD
At 2007-06-30-430USD
At 2007-06-20100USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-2,333,378USD90
2013-07-01 to 2014-03-31-4,906,894USD274
2007-06-21 to 2014-03-31-24,393,529USD2476
2012-07-01 to 2013-06-30-3,224,482USD365
2013-01-01 to 2013-03-31-866,550USD90
2012-07-01 to 2013-03-31-2,084,362USD274
2011-07-01 to 2012-06-30-4,894,402USD366
2010-07-01 to 2011-06-30-5,938,297USD365
2009-07-01 to 2010-06-30-3,433,400USD365
2008-07-01 to 2009-06-30-1,485,331USD365
2007-07-01 to 2008-06-30-510,193USD366
2007-06-21 to 2007-06-30-530USD10

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-03-3140,950USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-2,282,821USD90
2013-07-01 to 2014-03-31-4,747,674USD274
2007-06-21 to 2014-03-31-22,969,927USD2476
2013-01-01 to 2013-03-31-800,751USD90
2012-07-01 to 2013-03-31-1,898,403USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-03-315,360,921USD
At 2013-06-302,960,113USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2014-01-01 to 2014-03-3150,557USD90
2013-07-01 to 2014-03-31159,652USD274
2007-06-21 to 2014-03-31984,142USD2476
2013-01-01 to 2013-03-3165,799USD90
2012-07-01 to 2013-03-31185,959USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-03-319,391,017USD
At 2013-06-308,140,675USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2014-03-311,818,323USD
At 2013-06-301,849,077USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2014-03-314,557,310USD
At 2013-06-3010,400USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2014-01-01 to 2014-03-312,282,821USD90
2013-07-01 to 2014-03-314,747,674USD274
2007-06-21 to 2014-03-3122,969,927USD2476
2013-01-01 to 2013-03-31800,751USD90
2012-07-01 to 2013-03-311,898,403USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-01-01 to 2014-03-311,831,373USD90
2013-07-01 to 2014-03-313,417,149USD274
2007-06-21 to 2014-03-3110,024,042USD2476
2013-01-01 to 2013-03-31543,115USD90
2012-07-01 to 2013-03-311,009,584USD274

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-03-3125,580,323USD
At 2013-06-3014,868,223USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2014-03-31915,488USD
At 2013-06-30553,797USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-2,333,378USD90
2013-07-01 to 2014-03-31-4,906,894USD274
2007-06-21 to 2014-03-31-24,393,529USD2476
2013-01-01 to 2013-03-31-866,550USD90
2012-07-01 to 2013-03-31-2,084,362USD274

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-2,333,378USD90
2013-07-01 to 2014-03-31-6,886,600USD274
2007-06-21 to 2014-03-31-26,650,723USD2476
2013-01-01 to 2013-03-31-866,550USD90
2012-07-01 to 2013-03-31-2,296,164USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-03-31126,663USD90
2013-07-01 to 2014-03-31561,838USD274
2007-06-21 to 2014-03-311,466,470USD2476
2013-01-01 to 2013-03-3133,388USD90
2012-07-01 to 2013-03-3185,675USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2013-07-01 to 2014-03-312,067USD274
2007-06-21 to 2014-03-312,067USD2476

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2014-01-01 to 2014-03-3194,000USD90
2013-07-01 to 2014-03-31195,788USD274
2007-06-21 to 2014-03-31196,404USD2476
2013-01-01 to 2013-03-310USD90
2012-07-01 to 2013-03-31554USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-50,557USD90
2013-07-01 to 2014-03-31-159,220USD274
2007-06-21 to 2014-03-31-1,423,602USD2476
2013-01-01 to 2013-03-31-65,799USD90
2012-07-01 to 2013-03-31-185,959USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2013-07-01 to 2014-03-31-30,754USD274
2007-06-21 to 2014-03-311,818,372USD2476
2012-07-01 to 2013-03-3116,205USD274

Inspect the source

Entity
INNOVATION PHARMACEUTICALS INC. / CIK 0001355250
Captured
SEC response SHA-256
16f9a46a953f907c1d086cad016a5b045e6ee1cf4337a7d155b3765e6da56523

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001355250.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))